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DIFFUSION OF NEWLY-APPROVED GENERIC DRUG
PRODUCT USE WITHIN A STATE EMPLOYEE PRESCRIPTION
DRUG PROGRAM: A COMPARISON OF MAIL ORDER VERSUS
RETAIL PHARMACY CLAIMS
Johnsrud M
The University of Texas at Austin, Austin,TX, USA
OBJECTIVES: Pharmacy beneﬁt managers (PBMs) market their
ability to accelerate use of newly-approved generic drugs among
enrollees based upon the use of the PBMs’ wholly-owned mail
order drug facilities. Higher utilization rates of newly-approved
generic drugs result in an economic beneﬁt to enrollees and
plans. This study examines the differences in the diffusion of a
newly-approved generic drug product between mail order and
retail pharmacy channels. METHODS: Pharmacy claims data
for branded and generic versions of citalopram were collected
from a large state employee prescription drug program in Texas
consisting of over 400,000 enrollees beginning in November
2004 (representing the launch date of the newly-approved
generic). In addition, claims data were collected from the Texas
Medicaid Prescription Program during the same time period, for
comparison. Claims were collected for the ﬁrst six months post-
generic launch. Total outstanding “drug product in possession”
was calculated for each day post-generic launch based upon a
sum of the days supply for the branded and generic drug for
claims dispensed previous to, and during, the post-launch period.
Trends were examined in the percent of total outstanding days
supply represented by the branded or generic citalopram.
RESULTS: At days 30, 60, 90, and 120 post-generic drug launch,
percentage of generic drug product utilization (based upon out-
standing days supply) for mail order claims was 22%, 53%,
91%, and 96%. Retail claims showed generic utilization of 52%,
70%, 74%, and 78%. Medicaid program rates were 9%, 37%,
56% and 72%, respectively. Mail order generic utilization rates
of citalopram were lower than retail pharmacy utilization rates
until day 77 post-generic drug launch. CONCLUSIONS: While
the mail order pharmacy channel realized higher utilization rates
over the retail pharmacy channel of a newly-approved generic
drug product at four months post-launch, rates were higher in
retail setting during the ﬁrst 11 weeks.
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PREDICTORS FOR REHOSPITALIZATION IN PATIENTS 
WITH SCHIZOPHRENIA
Gothe H1, Höer A1, Seidlitz C1,Wittrup-Jensen KU2, Glaeske G3
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OBJECTIVES: Frequent rehospitalizations characterize the
course of schizophrenia. Though, knowledge about the impor-
tance of potential predictors for rehospitalization is limited. In
order to identify such predictors, the course of disease in schizo-
phrenic patients was analysed. METHODS: Claims data of a large
German sickness fund for the years 2000 to 2003 were used. A
sample of 2023 patients with an index hospitalization due to
schizophrenia (ICD-10: F20, F25) was drawn. The minimum
observation time for beneﬁciaries had to be 360 days. Cox-regres-
sion analysis was performed to estimate predictors for rehospi-
talization. RESULTS: A total of 1095 patients (54.1%) were
readmitted to hospital after 635 days (median). After discharge,
median duration until further hospitalization was 400 days (3rd
hospitalization), 287 days (4th hospitalization) and 160 days (5th
hospitalization), respectively. Patients with index hospitalizations
showed a signiﬁcantly higher risk for rehospitalization if they had
an inpatient stay due to acute exacerbation compared to patients
with rehabilitative care (relative risk (RR) 3.25; 95%CI
1.91–5.51; p < 0.001). Further predictors of rehospitalizations
were: substance abuse (RR 1.87; 95%CI 1.39–2.51; p < 0.001)
and duration of the index-case longer than 30 days. Patients with
schizoaffective disorders (ICD-10: F25) had a signiﬁcantly lower
risk than patients with schizophrenia (ICD-10: F20) (RR 0.58;
95%CI 0.46–0.74; p < 0.001). A lower risk was also observed in
beneﬁciaries aged 60 years and older (RR 0.50; 95%CI
0.33–0.75; p = 0.11). CONCLUSION: The following predictors
for rehospitalization have been identiﬁed: former hospitalization
due to acute exacerbation, duration of previous hospitalization,
younger age, and substance abuse. The more cases were observed,
the shorter the intervals between two hospitalizations became.
This illustrates the dynamics of the course of schizophrenia which
can be observed in longitudinal analyses of claims data.
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ANALYSIS OF A MULTINATIONAL, CROSS-SECTIONAL
SURVEY OF PHYSICIAN DESCRIPTIONS AND PERCEPTIONS
OF PATIENTS WITH NEGATIVE SYMPTOMS OF
SCHIZOPHRENIA
Leeuwenkamp O1, Perry R2, Milligan G2, Morlock R3, Lecrubier Y4
1Organon International, Molenstraat, Oss,The Netherlands, 2Adelphi
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OBJECTIVES: To assess physicians’ antipsychotic drug pre-
scribing practices, patient descriptions, and perceptions of nega-
tive symptoms. METHODS: Psychiatrists in the United States
and 5 European countries who prescribed antipsychotics for ≥15
patients with schizophrenia within the preceding 3 months com-
pleted a questionnaire concerning their patients’ clinical status
and therapy. RESULTS: Data for 6523 patients were collected
from 872 physicians. Two thirds of patients were outpatients,
63% were men, most were aged 25–44 years, and 50% were
unemployed. 50% of patients were rated as moderately to
grossly dysfunctional; 34% and 75% were taking conventional
or atypical antipsychotics, respectively. The most frequent nega-
tive symptoms were social withdrawal (54%), impoverished
thought (39%), and blunted affect (38%). Reasons for prescrib-
ing antipsychotic drugs included efﬁcacy for positive symptoms
(90%), efﬁcacy for negative symptoms (62%), and tolerability
(47%). Inadequate control of symptoms was higher for negative
symptoms (71%–77%) than for positive symptoms (47%–60%);
physicians viewed currently available atypical antipsychotics as
less effective against negative than positive symptoms but more
effective than conventional antipsychotics for negative symp-
toms. Adverse events associated with patients’ current antipsy-
chotic treatment included sedation (22%), weight gain (22%),
and extrapyramidal symptoms/parkinsonism (13%). A total of
579 patients (9%) were categorized as having predominant 
negative symptoms. In this patient subset, negative symptoms
occurred more often than positive symptoms, were more often
the reason for prescription, and were less likely to be adequately
controlled. However, use of atypical antipsychotics was similar
to use in other patients. CONCLUSIONS: This large, multina-
tional, cross-sectional physician survey involving a naturalistic
sample of patients with schizophrenia identiﬁed more effective
treatment of negative symptoms as a key unmet need, especially
in patients with predominant negative symptoms.
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OBJECTIVES: To construct and analyze a Structural Equation
Model (SEM) for Early Retirement (ER) of schizophrenia
patients in Germany and potential factors predisposing to ER.
METHODS: Based on a set of data consisting of 20 variables
collected retrospectively for 305 early retired and 317 not early
retired German Schizophrenia outpatients (mean age 38.7 years,
mean age at ﬁrst diagnosis 30.5 years), a SEM (Muthen &
Muthen) was constructed using MPlus 3.31 to model the rela-
tionship of potential predisposing factors among each other and
with the dichotomous outcome ER. RESULTS: The ﬁnal model
was based on 497 observations and included ER and the vari-
ables Disease Severity (CGI scale), Course of Disease (categories
from “continuous” to “remission”), Caring Situation (housing
and care information), Age, and Treatment with Atypical
Antipsychotics. Age (0.117), Caring Situation (0.134), Course of
Disease (−0.196) and Disease Severity (0.574) were directly
related to the outcome Early Retirement (values between 0 and
+/−1, positive: factor predisposes to ER). Indirect effects were
shown for Treatment with Atypical Antipsychotics, which nega-
tively inﬂuenced Disease Severity (−0.110); Age, which nega-
tively inﬂuenced the probability to receive Treatment with
Atypical Antipsychotics (−0.155); Caring Situation, which posi-
tively inﬂuenced Disease Severity (0.189); and Course of Disease,
which negatively inﬂuenced Disease Severity (−0.410). With a
variability of 0.538 explained and with all relationships signiﬁ-
cant, the model was highly valid. CONCLUSIONS: Disease
Severity is the central factor inﬂuencing the propensity of
German Schizophrenia Patients to ER. Course of Disease and
Caring Situation impact ER directly and also indirectly via
Disease Severity. Treatment with Atypical Antipsychotics reduces
the propensity to ER indirectly through the factor Disease Sever-
ity. Especially for ER as a dichotomous variable, SEMs can be
successfully used to analyze complex relationships between a set
of factors and the outcome of interest. Indirect effects can be
directly analyzed and displayed.
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OBJECTIVES: An interim analysis of changes in illness severity
(Clinical Global Impression-Severity, CGI-S) and functioning
(Global Assessment of Functioning, GAF) in Belgian patients
with schizophrenia switched to RLAI as part of their routine
management and followed up for 6 months. METHODS: e-
STAR is an observational study of patients using a web-based
data collection tool. Data are collected for 12 months retro-
spectively and 2 years prospectively for patients commencing a
new antipsychotic treatment. Data reported here are for those
patients who continue RLAI for 6 months. RESULTS: In Belgium
400 patients have been enrolled. Of the 206 patients with 6
months follow-up data, 86% (178 patients) have continued
treatment with RLAI. Mean (SD) age of this group of patients
was 40.3 (13.7) years. Mean (SD) duration of illness was 10.4
(10.3) and 62.4% were male. Most frequent reasons for a switch
to RLAI were poor compliance (38.2% of patients) and need for
maintenance therapy (23.5%). Mean (SD, median) CGI score 
at baseline was 4.5 (1.0, 5.0) (n = 142) with 16.9% patients
having very mild/mild illness, 30.3% moderate, and 52.8%
marked/severe/very severe. At 6 months, mean (SD, median) CGI
score was signiﬁcantly lower at 3.5 (1.1, 3.0) (p < 0.001) with
52.1% having mild/very mild illness (p < 0.001 versus baseline),
29.6% moderate and 18.3% marked/severe/very severe (p <
0.001). Similarly mean (SD, median) GAF score improved from
45.3 (13.6, 45.0) at baseline to 59.6 (13.7, 60.5) at 6 months (n
= 142) (p < 0.001). RLAI was well tolerated; 88.8% of patients
reported no adverse events (AEs). Serious AEs were reported in
8 (4.5%) patients, none of which were unequivocally related to
RLAI. CONCLUSIONS: These interim data show that patients
who switched to RLAI exhibit signiﬁcant improvements from
baseline in clinical and functional outcomes after 6 months of
continual treatment. Further follow-up is ongoing.
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REDUCTION IN SUICIDAL IDEATION AND VIOLENT
BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH
LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN
THE ELECTRONIC SCHIZOPHRENIA ADHERENCE
TREATMENT REGISTRY (E-STAR)
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OBJECTIVES: To examine whether there is a reduced incidence
of suicidal ideation, violent behaviour, and deliberate self-harm
in patients with schizophrenia after six months of treatment with
long-acting risperidone injection (RLAI). METHODS: e-STAR 
is an ongoing, multinational, non-interventional, observational
registry that records outcomes following a change in antipsy-
chotic drug treatment during the management of patients with
schizophrenia in a normal clinical practice setting. The incidence
of suicidal ideation, violent behaviour, and deliberate self-harm
(secondary objectives of the registry) were assessed at baseline
and after six months of treatment with RLAI. RESULTS: Interim
data are available for a total 1571 patients in Spain (n = 1005),
Belgium (n = 178), and Australia (n = 388). There was a statis-
tically signiﬁcant reduction in the incidence of suicidal ideation
in Spanish patients (9.4% at baseline versus 0.4% at six months,
p < 0.001) and Belgian patients (6.2% versus 0.6%, p = 0.004)
after six months of treatment with RLAI. Although there was a
reduction in suicidal ideation in Australian patients (6.4% versus
5.2%), this was not statistically signiﬁcant. There was a statisti-
cally signiﬁcant reduction in violent behaviour in Spanish
patients (11.1% versus 0.3%, p < 0.001), Belgian patients
(11.2% versus 0.6%, p < 0.001), and Australian patients (9.0%
versus 4.9%, p < 0.02) after six months. In Spain, there was a
decreased incidence of deliberate self-harm after six months of
treatment (3% versus 0%) and this was also seen in Belgian
patients (1.7% to 0%). In Australia, the incidence of deliberate
self-harm was unchanged at 2.8%. CONCLUSIONS: There was
a reduction in suicidal ideation and violent behaviour after six
months of treatment with RLAI in Spanish, Belgian, and Aus-
tralian patients with schizophrenia.
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SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-
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RISPERIDONE LONG-ACTING INJECTION (RLAI)
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OBJECTIVES: This is a 6-month interim analysis of patients in
Spain who are enrolled in e-STAR, and initiated on RLAI during
